Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PLM035
MIFTS: 48

Pulmonary Eosinophilia

Categories: Blood diseases, Respiratory diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Pulmonary Eosinophilia

About this section

MalaCards integrated aliases for Pulmonary Eosinophilia:

Name: Pulmonary Eosinophilia 12 54 15 71
Asthmatic Pulmonary Eosinophilia 71

Classifications:

MalaCards categories:
Anatomical: Respiratory diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:9498
ICD9CM 34 518.3
MeSH 43 D011657
SNOMED-CT 67 367542003
ICD10 32 J82
UMLS 71 C0034068 C0340076
Sources

Summaries for Pulmonary Eosinophilia

About this section
Disease Ontology : 12 A hypereosinophilic syndrome characterized by the accumulation of eosinophils in the lungs.

MalaCards based summary : Pulmonary Eosinophilia, also known as asthmatic pulmonary eosinophilia, is related to loeffler syndrome and chronic eosinophilic pneumonia, and has symptoms including hemoptysis An important gene associated with Pulmonary Eosinophilia is IL5 (Interleukin 5), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Nitric Oxide and Ciclesonide have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and testes, and related phenotypes are hematopoietic system and immune system

Sources

Related Diseases for Pulmonary Eosinophilia

About this section

Diseases related to Pulmonary Eosinophilia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 289)
# Related Disease Score Top Affiliating Genes
1 loeffler syndrome 33.5 IL5 IL13 CCR3
2 chronic eosinophilic pneumonia 33.3 RNASE3 IL5 CCL5 CCL3 CCL11
3 ascaris lumbricoides infection 31.8 IL5 IL13 CXCL8
4 eosinophilic pneumonia 31.1 SFTPD RNASE3 IL5 IL4 IL13 CXCL8
5 filarial elephantiasis 30.7 IL5 IL4 IL13
6 toxocariasis 30.6 RNASE3 IL5 IL4
7 cytokine deficiency 30.4 IL5 IL13
8 elephantiasis 30.4 RNASE3 IL5 IL4 IL13
9 respiratory syncytial virus infectious disease 30.0 IL5 IL13 CCL5 CCL3
10 folliculitis 29.5 IL5 IL4 CCR6 CCL5 CCL11
11 exanthem 29.4 CXCL8 CSF2 CCR6
12 mycobacterium tuberculosis 1 29.3 SERPINA1 IL4 CCR6 CCL3
13 myelitis 29.2 CXCL8 CCR6 CCL11
14 pneumoconiosis 29.1 SERPINA1 IL4 CXCL8
15 allergic bronchopulmonary aspergillosis 29.1 SFTPD IL5 IL4 EPX CCR3 CCL17
16 bronchiolitis obliterans 29.0 SFTPD IL13 CXCL8
17 pulmonary fibrosis 28.9 SFTPD IL13 CXCL8 CCL3 CCL17
18 sarcoidosis 1 28.8 SFTPD IL13 CCR6 CCL5 CCL3 CCL11
19 churg-strauss syndrome 28.7 RNASE3 PRG2 IL5 CYSLTR1 CXCL8 CCL17
20 leprosy 3 28.6 IL5 IL4 CXCL8 CSF2 CCR6
21 allergic asthma 28.3 RNASE3 IL5 IL4 IL13 EPX CXCL8
22 interstitial lung disease 28.3 SFTPD IL5 IL4 IL13 CXCL8 CSF2
23 dermatitis 28.2 IL5 IL4 IL13 CXCL8 CCR6 CCL17
24 bronchiolitis 28.2 SFTPD RNASE3 IL5 IL4 IL13 CXCL8
25 connective tissue disease 28.2 SFTPD PRG2 IL4 CXCL8 CCR6
26 bronchitis 28.1 SERPINA1 RNASE3 IL5 IL4 IL13 CXCL8
27 hypereosinophilic syndrome 27.9 RNASE3 PRG2 IL5 IL4 IL13 EPX
28 aspergillosis 27.5 SFTPD IL5 IL4 EPX CXCL8 CSF2
29 pneumonia 27.1 SFTPD SERPINA1 IL5 IL4 IL13 CXCL8
30 lung disease 27.0 SFTPD SERPINA1 RNASE3 PDE4A IL5 IL4
31 allergic rhinitis 26.8 RNASE3 IL5 IL4 IL13 EPX CXCL8
32 rhinitis 26.8 RNASE3 PRG2 IL5 IL4 IL13 EPX
33 respiratory failure 26.6 SFTPD SERPINA1 RNASE3 PDE4A IL5 IL13
34 allergic hypersensitivity disease 25.4 SFTPD RNASE3 IL5 IL4 IL13 EPX
35 asthma 23.8 SFTPD SERPINA1 RNASE3 RNASE2 PRG2 PDE4A
36 idiopathic eosinophilic pneumonia 10.9
37 idiopathic acute eosinophilic pneumonia 10.8
38 aztreonam allergy 10.5 IL5 IL13
39 angioimmunoblastic lymphadenopathy with dysproteinemia 10.5 IL5 IL13
40 allergic encephalomyelitis 10.5 CCL5 CCL3
41 cefaclor allergy 10.4 IL5 IL13
42 pemphigoid gestationis 10.4 RNASE3 IL5 CCL11
43 cefuroxime allergy 10.4 IL5 IL13
44 whiplash 10.4 CCL5 CCL3
45 chronic meningitis 10.4 IL5 IL13 CCL11
46 cow milk allergy 10.4 RNASE3 IL5 IL4
47 ceftriaxone allergy 10.4 IL5 IL13
48 strongyloidiasis 10.4 IL5 IL13 CCL11
49 trichinosis 10.4 IL5 IL4 IL13
50 filariasis 10.4

Comorbidity relations with Pulmonary Eosinophilia via Phenotypic Disease Network (PDN): (show all 13)


Active Peptic Ulcer Disease Acute Cystitis
Bronchitis Decubitus Ulcer
Deficiency Anemia Esophagitis
Familial Atrial Fibrillation Heart Disease
Iron Deficiency Anemia Postinflammatory Pulmonary Fibrosis
Protein-Energy Malnutrition Respiratory Failure
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Pulmonary Eosinophilia:



Diseases related to Pulmonary Eosinophilia
Sources

Symptoms & Phenotypes for Pulmonary Eosinophilia

About this section

UMLS symptoms related to Pulmonary Eosinophilia:


hemoptysis

MGI Mouse Phenotypes related to Pulmonary Eosinophilia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.93 CCL11 CCL17 CCL5 CCR3 CCR6 CSF2
2 immune system MP:0005387 9.8 CCL11 CCL17 CCL5 CCR3 CCR6 CSF2
3 respiratory system MP:0005388 9.28 CCL11 CCR3 CSF2 CYSLTR1 IL13 IL4
Sources

Drugs & Therapeutics for Pulmonary Eosinophilia

About this section

Drugs for Pulmonary Eosinophilia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 63)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nitric Oxide Approved Phase 4 10102-43-9 145068
2
Ciclesonide Approved, Investigational Phase 4 141845-82-1, 126544-47-6 444033
3
Omalizumab Approved, Investigational Phase 4 242138-07-4
4
Azithromycin Approved Phase 4 83905-01-5 447043 55185
5
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
6
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
7
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
8
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
9 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
10 Benralizumab Approved, Investigational Phase 4 1044511-01-4
11
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
12
Budesonide Approved Phase 4 51333-22-3 63006 5281004
13
tannic acid Approved Phase 4 1401-55-4
14
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
15
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
16 Gastrointestinal Agents Phase 4
17 Neuroprotective Agents Phase 4
18 Antiemetics Phase 4
19 Anti-Allergic Agents Phase 4
20 Antibodies Phase 4
21 Antibodies, Monoclonal Phase 4
22 Immunoglobulins Phase 4
23 Antiviral Agents Phase 4
24 Anti-Bacterial Agents Phase 4
25 Anti-Infective Agents Phase 4
26 Hormones Phase 4
27 Methylprednisolone Acetate Phase 4
28 glucocorticoids Phase 4
29 Antineoplastic Agents, Hormonal Phase 4
30 Hormone Antagonists Phase 4
31 Anti-Inflammatory Agents Phase 4
32 Respiratory System Agents Phase 4
33 Anti-Asthmatic Agents Phase 4
34 Neurotransmitter Agents Phase 4
35 Adrenergic beta-Agonists Phase 4
36 Adrenergic Agents Phase 4
37 Albuterol Phase 4
38 Adrenergic Agonists Phase 4
39 Tocolytic Agents Phase 4
40 Bronchodilator Agents Phase 4
41 Formoterol Fumarate Phase 4
42 Budesonide, Formoterol Fumarate Drug Combination Phase 4
43
Reslizumab Approved, Investigational Phase 3 241473-69-8
44 Pharmaceutical Solutions Phase 3
45 Immunoglobulins, Intravenous Phase 3
46 Immunoglobulin G Phase 3
47 Protective Agents Phase 3
48 Antioxidants Phase 3
49 silymarin Phase 3
50
Fluticasone Approved, Experimental Phase 2 90566-53-3 62924

Interventional clinical trials:

(show all 44)
# Name Status NCT ID Phase Drugs
1 Phase 4, Randomized Study of Three Months-prednisolone Therapy in the Treatment of Chronic Eosinophilic Pneumonia Completed NCT00632554 Phase 4 prednisolone 0.5 mg/kg/day for three months;prednisolone 0.5 mg/kg/day for six months
2 Small Particle Inhaled Steroids in Refractory Steroid-responsive Asthma Completed NCT01171365 Phase 4 Ciclesonide;Placebo
3 A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study) Completed NCT02654145 Phase 4 Mepolizumab 100mg SC;Albuterol/salbutamol MDIs;Omalizumab
4 Effects of Azithromycin Treatment on Anti-viral Immunity in Patients With Asthma and COPD - A Randomized Double-blind, Placebo-controlled Trial Recruiting NCT04319705 Phase 4 Azithromycin;Placebo oral tablet
5 A Pragmatic Study to Investigate the Efficacy and Safety of Mepolizumab in Severe Uncontrolled Asthma in Brazil Recruiting NCT04228588 Phase 4 Mepolizumab 100 MG [Nucala]
6 Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma Not yet recruiting NCT03652376 Phase 4 Benralizumab
7 SHAMAL: A Multicentre, Randomised, Open-Label, Parallel-Group, Active-Controlled, Phase IV Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab Not yet recruiting NCT04159519 Phase 4 Symbicort®;Fasenra®;Ventolin®
8 A Phase 4, Open-label, Single Arm, 24-week, Phase 4 Study to Evaluate the Safety and Efficacy of Mepolizumab 100 mg SC Administered Every 4 Weeks in Indian Participants Aged >=18 Years With Severe Eosinophilic Asthma Requiring Oral Corticosteroid Treatment to Maintain Asthma Control (PRISM) Not yet recruiting NCT04276233 Phase 4 Prednisone/ Prednisolone;Salbutamol
9 A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01285323 Phase 3 Reslizumab;Placebo
10 A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01270464 Phase 3 Reslizumab;Placebo
11 A 16-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) Treatment in Patients With Moderate to Severe Asthma Completed NCT01508936 Phase 3 Reslizumab;Placebo
12 A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre 24-week Study to Evaluate the Efficacy and Safety of Mepolizumab Adjunctive Therapy in Subjects With Severe Eosinophilic Asthma on Markers of Asthma Control Completed NCT02281318 Phase 3 Placebo;SOC
13 A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01287039 Phase 3 Reslizumab;Placebo
14 A Multi-center, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Compare Cessation Versus Continuation of Long-term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma (201810) Completed NCT02555371 Phase 3 Placebo
15 Route of Administration of Anti-IL5 Monoclonal Antibody in Prednisone-dependent Eosinophilic Asthma Completed NCT02559791 Phase 2, Phase 3 Placebo
16 Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies Recruiting NCT03470311 Phase 3
17 A 52 Week, Randomised, Double Blind, Multinational, Multicentre, 4-arm Parallel Group Trial to Assess the Efficacy and Safety of 3 Doses of CHF 6532 Compared to Placebo on Top of Standard of Care in Patients With Uncontrolled Severe Eosinophilic Asthma Recruiting NCT04049175 Phase 3 Treatment A;Treatment B;Treatment C;Treatment D
18 An Open-label Study to Evaluate the Pharmacokinetics and Pharmacodynamics and Long-term Safety of Benralizumab Administered Subcutaneously in Children With Severe Eosinophilic Asthma Active, not recruiting NCT04305405 Phase 3 Benralizumab
19 Trial of Silymarin in Adults With COVID-19 Pneumonia Not yet recruiting NCT04394208 Phase 3 Silymarin;Placebo
20 An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma Terminated NCT03052725 Phase 3 reslizumab
21 An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients With Eosinophilic Asthma Who Completed a Prior Teva-Sponsored Study in Eosinophilic Asthma Terminated NCT01290887 Phase 3 Reslizumab
22 A Randomized, Double-blind, Placebo-controlled, Mono-center Study to Evaluate the Effects of Mepolizumab on Airway Physiology in Patients With Eosinophilic Asthma: the MEMORY Study Terminated NCT02594332 Phase 3 Mepolizumab;Placebo
23 Placebo Controlled Proof of Concept Study to Investigate ANB020 Activity in Adult Patients With Severe Eosinophilic Asthma Completed NCT03469934 Phase 2 ANB020;Placebo
24 The Effect of OC000459 on Eosinophilic Airway Inflammation and Asthma Control in Subjects With Refractory Eosinophilic Asthma: a Randomised, Double-blind, Placebo Controlled Trial Completed NCT02560610 Phase 2 OC000459;Placebo
25 Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of SAR231893/REGN668 Administered Subcutaneously Once Weekly for 12 Weeks in Patients With Persistent Moderate to Severe Eosinophilic Asthma Who Are Partially Controlled/Uncontrolled by Inhaled Corticosteroid Plus Long-acting beta2 Agonist Therapy Completed NCT01312961 Phase 2 Dupilumab;Placebo (for Dupilumab);Fluticasone/Salmeterol combination therapy;Fluticasone monotherapy;Albuterol;Levalbuterol
26 A Phase IIa , Double-blind, Placebo-controlled Dose-ranging Study to Evaluate the Efficacy and Safety of KHK4563 in Adults With Uncontrolled, Suspected Eosinophilic Asthma Completed NCT01412736 Phase 2 KHK4563;KHK4563;KHK4563;Placebo
27 A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Biomarker Study of the Effects of Dexpramipexole on Eosinophils in Subjects With Eosinophilic Asthma Recruiting NCT04046939 Phase 2 low-dose dexpramipexole;mid-dose dexpramipexole;high-dose dexpramipexole;placebo oral tablet
28 Usefulness of Exhaled NO in the Differential Diagnosis Acute Eosinophilic Pneumonia and Community Acquired Pneumonia Unknown status NCT01152424
29 Serum Cytokine Profiles of Severe Asthma Completed NCT03563521
30 Observational Retrospective Study to Characterise Patients Receiving Benralizumab in the Framework of an Individualized Access Program in Spain Completed NCT04126499
31 Characteristics of the Eosinophilic Asthma Phenotype: an Observational Study in Patients From a Tertiary Care Center With Various Asthma Severities: The Quebec Heart and Lung Institute-Laval University Retrospective Asthma Database Analysis Completed NCT03696914
32 Effet du Mepolizumab Sur la décroissance de la corticothérapie systémique Chez Des Patients Avec un Asthme éosinophilique sévère Etude Observationnelle, Suivi de Cohorte Via Une ATU Nominative Completed NCT03453021 Mepolizumab
33 Description of Eosinophilic Pneumonia in BJI/PJI Treated by Daptomycin Recruiting NCT04414137
34 imPROve-asthma - A Prospective, 12-month, Observational Study to Investigate the Change in Patient-Reported Outcomes in Severe Eosinophilic Asthma Patients Treated With Benralizumab Biologic Therapy Under Real-life Conditions in Germany Recruiting NCT04184284
35 A Multicentre Single Arm Observational Prospective Study to Assess Demographic Characteristics Burden of Disease PRO's in Uncontrolled, Severe Eosinophilic Asthma Patients Aged 18y or Older and Qualifying for Treatment With Benralizumab in BE Recruiting NCT04221802
36 Patient Outcomes Real World Evidence Registry (POWER): Patient Reported Outcomes in a Cohort of Canadian Adults With Severe Eosinophilic Asthma on Benralizumab. Recruiting NCT03833141
37 A Prospective Observational Study on the Effect of Mepolizumab add-on Therapy on Daily Physical Activity in Patients With Severe Eosinophilic Asthma Recruiting NCT03739320 Mepolizumab 100 MG Injection [Nucala]
38 Effects of Anti-IL5 Biological Treatments of Total Blood IgE Levels in Severe Asthmatic Patients: Real-life Retrospective Multicenter Observational Study Recruiting NCT04181190
39 A Multicentre, Single Arm, Observational, Prospective Study to Assess Demographic Characteristics, Burden of Disease and Short-term Patient Reported Outcomes on Symptom Relief in Severe Eosinophilic Asthma Patients Older Than 18 Starting Benralizumab in Switzerland Recruiting NCT03907137
40 Orphans Unite: chILD Better Together - European Management Platform for Childhood Interstitial Lung Diseases / chILD-EU - International Register and Biobank for Children´s Interstital Lung Disease Recruiting NCT02852928
41 Computed Tomography Air-trapping Characterisation for the Early Identification of Benralizumab Responders Among Eosinophilic Asthma Patients Recruiting NCT03976310 48 weeks of Benralizumab
42 Mepolizumab: Real World Evidence Study for the Treatment of Severe Eosinophilic Asthma in Greece Active, not recruiting NCT04084613
43 A Mechanistic Pilot Open-label Study to Evaluate the Effect of Benralizumab on Airway Function and Inflammation in Patients With Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI Active, not recruiting NCT03733535 Benralizumab;129 Xenon
44 Peripheral Eosinophils Phenotypes in Airway Inflammatory Diseases: Towards Proper Clustering and Therapeutic Targeting Not yet recruiting NCT04187976

Search NIH Clinical Center for Pulmonary Eosinophilia

Sources

Genetic Tests for Pulmonary Eosinophilia

About this section
Sources

Anatomical Context for Pulmonary Eosinophilia

About this section

MalaCards organs/tissues related to Pulmonary Eosinophilia:

40
Lung, T Cells, Testes, Heart, Bone Marrow, Bone, Neutrophil
Sources

Publications for Pulmonary Eosinophilia

About this section

Articles related to Pulmonary Eosinophilia:

(show top 50) (show all 778)
# Title Authors PMID Year
1
Clinical alterations and mRNA levels of IL-4 and IL-5 in bronchoalveolar cells of horses with transient pulmonary eosinophilia. 54 61
17996260 2008
2
Tropical pulmonary eosinophilia: pathogenesis, diagnosis and management. 61 54
17940489 2007
3
Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354). 61 54
16120093 2005
4
Genetic polymorphisms of eosinophil-derived neurotoxin and eosinophil cationic protein in tropical pulmonary eosinophilia. 61 54
16014847 2005
5
Susceptibility of mice genetically deficient in the surfactant protein (SP)-A or SP-D gene to pulmonary hypersensitivity induced by antigens and allergens of Aspergillus fumigatus. 54 61
15905537 2005
6
Safety and efficacy of immune-stimulating complex-based antigen delivery systems for neonatal immunisation against respiratory syncytial virus infection. 61 54
15158774 2004
7
Allergen-induced fluctuation in CC chemokine receptor 3 expression on bone marrow CD34+ cells from asthmatic subjects: significance for mobilization of haemopoietic progenitor cells in allergic inflammation. 54 61
12871220 2003
8
Elevated immunoglobulin E against recombinant Brugia malayi gamma-glutamyl transpeptidase in patients with bancroftian filariasis: association with tropical pulmonary eosinophilia or putative immunity. 61 54
12540554 2003
9
Evidence for systemic rather than pulmonary effects of interleukin-5 administration in asthma. 54 61
11713356 2001
10
Glucocorticoid administration accelerates mortality of pneumovirus-infected mice. 54 61
11740726 2001
11
Identification of R146225 as a novel, orally active inhibitor of interleukin-5 biosynthesis. 61 54
11046102 2000
12
Pulmonary eosinophilia and production of MIP-1alpha are prominent responses to infection with pneumonia virus of mice. 54 61
10753501 2000
13
Mapping and characterization of the epitope(s) of Sch 55700, a humanized mAb, that inhibits human IL-5. 54 61
10590259 1999
14
Antigen-induced airway hyperresponsiveness, pulmonary eosinophilia, and chemokine expression in B cell-deficient mice. 54 61
10030835 1999
15
An essential role for interleukin-5 and eosinophils in helminth-induced airway hyperresponsiveness. 61 54
9712797 1998
16
IgE down regulation and cytokine induction by Aspergillus antigens in human allergic bronchopulmonary aspergillosis. 61 54
9523846 1998
17
Effects of a selective PDE4 inhibitor, D-22888, on human airways and eosinophils in vitro and late phase allergic pulmonary eosinophilia in guinea pigs. 61 54
9802959 1998
18
Kinetics of the development and recovery of the lung from IgE-mediated inflammation: dissociation of pulmonary eosinophilia, lung injury, and eosinophil-active cytokines. 61 54
9032176 1997
19
Cytokines as targets for the inhibition of eosinophilic inflammation. 61 54
9352584 1997
20
Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection. 61 54
8985399 1997
21
The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4. 61 54
8818342 1996
22
Eotaxin triggers eosinophil-selective chemotaxis and calcium flux via a distinct receptor and induces pulmonary eosinophilia in the presence of interleukin 5 in mice. 54 61
8784786 1996
23
Immunopurification and measurement of IgE in serum samples from bancroftian filariasis patients. 54 61
8627493 1996
24
Rapid and selective induction of blood eosinophilia in guinea pigs by recombinant human interleukin 5. 61 54
8664444 1995
25
Inhibition of pulmonary eosinophilia and hyperreactivity by antibodies to interleukin-5. 61 54
7613159 1995
26
Animal models of occupational asthma. 61 54
8013613 1994
27
Allergic bronchopulmonary mycosis complicating cystic fibrosis. 54 61
1475542 1992
28
Human eosinophil major basic protein induces airway constriction and airway hyperresponsiveness in primates. 54 61
2010556 1991
29
Frequency analysis of IgE-secreting B lymphocytes in persons with normal or elevated serum IgE levels. 54 61
1899687 1991
30
The BALB/c mouse as a model for immunological studies of microfilariae-induced pulmonary eosinophilia. 54 61
2382764 1990
31
Lung fibroblasts produce interleukin-33 in response to stimulation by retinoblastoma-binding protein 9 via production of prostaglandin E2. 61
32484881 2020
32
Eosinophilic Pneumonia and Lymphadenopathy Associated With Vaping and Tetrahydrocannabinol Use. 61
32217740 2020
33
Exon 8 KIT mutation and pulmonary eosinophilia. 61
32168380 2020
34
Filarial tropical pulmonary eosinophilia. 61
30720371 2020
35
Unilateral antibiotic-induced acute eosinophilic pneumonia on the operative side after surgery for primary lung cancer: a case report. 61
32076875 2020
36
Acute eosinophilic pneumonia associated with non-cigarette smoking products: a systematic review. 61
32383466 2020
37
Unexpected Outcome of Daptomycin-induced Eosinophilic Pneumonia: Rarity Within a Rarity. 61
31903307 2019
38
A tricky and rare cause of pulmonary eosinophilia: myeloid/lymphoid neoplasm with eosinophilia and rearrangement of PDGFRA. 61
31744552 2019
39
CD200R1 regulates eosinophilia during pulmonary fungal infection in mice. 61
31365119 2019
40
Recombinant live attenuated influenza vaccine viruses carrying CD8 T-cell epitopes of respiratory syncytial virus protect mice against both pathogens without inflammatory disease. 61
31075351 2019
41
Filarial tropical pulmonary eosinophilia: a condition masquerading asthma, a series of 12 cases. 61
29969926 2019
42
Diagnostic pitfalls of acute eosinophilic pneumonia in an adolescent boy following cigarette smoking: A case report. 61
31096462 2019
43
Cigarette smoking-induced acute eosinophilic pneumonia: A case report. 61
30817609 2019
44
TNF-α-Producing Cryptococcus neoformans Exerts Protective Effects on Host Defenses in Murine Pulmonary Cryptococcosis. 61
31404168 2019
45
Extracorporeal Membrane Oxygenation in Severe Acute Eosinophilic Pneumonia. 61
31024915 2019
46
Elevated Periostin Concentrations in the Bronchoalveolar Lavage Fluid of Patients with Eosinophilic Pneumonia. 61
30612125 2019
47
[Vasculitides and eosinophilic pulmonary diseases]. 61
30367242 2018
48
Mer-mediated eosinophil efferocytosis regulates resolution of allergic airway inflammation. 61
29428392 2018
49
Anti-Inflammatory Activities of Pentaherbs formula and Its Influence on Gut Microbiota in Allergic Asthma. 61
30373169 2018
50
BMS‑345541 inhibits airway inflammation and epithelial‑mesenchymal transition in airway remodeling of asthmatic mice. 61
30015827 2018
Sources

Variations for Pulmonary Eosinophilia

About this section
Sources

Expression for Pulmonary Eosinophilia

About this section
Search GEO for disease gene expression data for Pulmonary Eosinophilia.
Sources

Pathways for Pulmonary Eosinophilia

About this section

Pathways related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14 SERPINA1 RNASE3 RNASE2 PRG2 IL5 IL4
2
ERK Signaling 63
Show member pathways
 13.74 PRG2 IL5 IL4 IL13 CXCL8 CSF2
3
PEDF Induced Signaling 63
Show member pathways
 13.67 IL5 IL4 IL13 CXCL8 CSF2 CCR6
4
TGF-Beta Pathway 63
Show member pathways
 13.53 IL5 IL4 IL13 CXCL8 CCL7 CCL5
5
Integrin Pathway 63
Show member pathways
 13.39 PRG2 CXCL8 CCR6 CCR3 CCL7 CCL5
6
Cytokine Signaling in Immune system 65
Show member pathways
 13.34 IL5 IL4 IL13 CXCL8 CSF2 CCL5
7
Akt Signaling 63
Show member pathways
 13.33 IL5 IL4 IL13 CXCL8 CSF2 CCR6
8
PAK Pathway 63
Show member pathways
 13.21 IL5 IL4 IL13 CXCL8 CSF2 CCR6
9
CCR5 Pathway in Macrophages 63
Show member pathways
 12.88 CXCL8 CCR6 CCR3 CCL7 CCL5 CCL3
10
Allograft rejection 1 36
Show member pathways
 12.82 RNASE3 PRG2 IL5 IL4 IL13 EPX
11
Immune response CCR3 signaling in eosinophils 22
Show member pathways
 12.34 CXCL8 CCR3 CCL7 CCL5 CCL11
12
IL-17 Family Signaling Pathways 64
Show member pathways
 12.26 IL5 IL4 IL13 CXCL8 CSF2 CCL7
13
Chemokine Superfamily: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.19 CXCL8 CCR6 CCR3 CCL7 CCL5 CCL3
14
Bacterial infections in CF airways 22
Show member pathways
 12.16 SFTPD IL4 CXCL8 CCL11
15
Hematopoietic Stem Cells and Lineage-specific Markers 64
11.99 IL5 IL4 CSF2 CCR3
16
Interleukin-4 and 13 signaling 65
11.98 IL4 IL13 CXCL8 CCL11
17
Rheumatoid arthritis 36
11.87 CXCL8 CSF2 CCL5 CCL3
18
Hematopoietic cell lineage 36
11.82 IL5 IL4 CSF2
19
Glucocorticoid receptor regulatory network 1
11.82 IL5 IL4 IL13 CXCL8 CSF2
20
Innate Lymphoid Cells Differentiation 64
11.8 IL5 IL4 IL13 CCR6 CCL3
21
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.77 IL5 IL4 CXCL8 CSF2
22
IL4-mediated signaling events 1
11.68 IL5 IL4 CCL17 CCL11
23
Th2 Differentiation 64
11.49 IL5 IL4 IL13 CCL17 CCL11
24
Interleukin-10 signaling 65
11.32 IL4 IL13 CXCL8 CSF2 CCL5 CCL3
25
Development and heterogeneity of the ILC family 1
11.31 IL5 IL4 IL13
26
Cytokines and Inflammatory Response 1
11.3 IL5 IL4 IL13 CSF2
27
OX40 Pathway 63
11.2 IL5 IL4 IL13
28
Lung fibrosis 1
11.12 SERPINA1 IL5 IL4 IL13 CXCL8 CSF2
29
IL-9 Signaling and its Primary Biological Effects in Different Immune Cell Types 64
10.82 IL5 IL4 IL13
30
G-protein signaling_Rap2B regulation pathway 22
10.6 PRG2 IL5 IL4 IL13 CXCL8 CSF2
Sources

GO Terms for Pulmonary Eosinophilia

About this section

Cellular components related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.8 SFTPD SERPINA1 RNASE3 IL5 IL4 IL13
2 cell GO:0005623 9.76 IL13 CYSLTR1 CCR6 CCR3 CCL7 CCL5
3 extracellular region GO:0005576 9.53 SFTPD SERPINA1 RNASE3 RNASE2 PRG2 IL5

Biological processes related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.3 PDE4A IL5 IL4 CYSLTR1 CXCL8 CCR6
2 G protein-coupled receptor signaling pathway GO:0007186 10.21 PDE4A CYSLTR1 CXCL8 CCR6 CCR3 CCL7
3 neutrophil degranulation GO:0043312 10.04 SERPINA1 RNASE3 RNASE2 PRG2 EPX
4 positive regulation of GTPase activity GO:0043547 10.03 CCL7 CCL5 CCL3 CCL17 CCL11
5 positive regulation of cell migration GO:0030335 10.01 IL4 CCL7 CCL5 CCL3 CCL11
6 positive regulation of ERK1 and ERK2 cascade GO:0070374 10 CCL7 CCL5 CCL3 CCL17 CCL11
7 MAPK cascade GO:0000165 9.97 IL5 CSF2 CCL5 CCL3
8 defense response to bacterium GO:0042742 9.97 SFTPD RNASE3 PRG2 EPX
9 cell-cell signaling GO:0007267 9.95 CCL7 CCL5 CCL3 CCL17
10 cellular response to tumor necrosis factor GO:0071356 9.95 CXCL8 CCL7 CCL5 CCL3 CCL17 CCL11
11 cellular calcium ion homeostasis GO:0006874 9.92 CCL7 CCL5 CCL3 CCL11
12 cellular response to interferon-gamma GO:0071346 9.92 CCL7 CCL5 CCL3 CCL17 CCL11
13 cytokine-mediated signaling pathway GO:0019221 9.92 IL5 IL4 IL13 CXCL8 CSF2 CCL5
14 cell chemotaxis GO:0060326 9.91 CCR6 CCR3 CCL5 CCL3
15 inflammatory response GO:0006954 9.91 IL5 IL13 CXCL8 CCR3 CCL7 CCL5
16 calcium-mediated signaling GO:0019722 9.89 CXCL8 CCR6 CCR3 CCL3
17 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.88 IL4 IL13 CSF2 CCL5
18 cellular response to interleukin-1 GO:0071347 9.88 CXCL8 CCL7 CCL5 CCL3 CCL17 CCL11
19 monocyte chemotaxis GO:0002548 9.85 CCL7 CCL5 CCL3 CCL17 CCL11
20 neutrophil chemotaxis GO:0030593 9.85 CXCL8 CCL7 CCL5 CCL3 CCL17 CCL11
21 lymphocyte chemotaxis GO:0048247 9.83 CCL7 CCL5 CCL3 CCL17 CCL11
22 positive regulation of B cell proliferation GO:0030890 9.8 IL5 IL4 IL13
23 eosinophil chemotaxis GO:0048245 9.8 CCL7 CCL5 CCL3 CCL11
24 chemokine-mediated signaling pathway GO:0070098 9.76 CXCL8 CCR6 CCR3 CCL7 CCL5 CCL3
25 macrophage chemotaxis GO:0048246 9.75 SFTPD CCL5 CCL3
26 macrophage activation GO:0042116 9.74 IL4 IL13 CSF2
27 induction of bacterial agglutination GO:0043152 9.72 SFTPD RNASE3 RNASE2
28 positive regulation of natural killer cell chemotaxis GO:2000503 9.71 CCL7 CCL5 CCL3
29 dendritic cell differentiation GO:0097028 9.68 IL4 CSF2
30 negative regulation of G protein-coupled receptor signaling pathway GO:0045744 9.67 CXCL8 CCL5
31 positive regulation of podosome assembly GO:0071803 9.66 IL5 CSF2
32 negative regulation by host of viral transcription GO:0043922 9.66 CCL5 CCL3
33 neutrophil activation GO:0042119 9.65 CXCL8 CCL5
34 positive regulation of interleukin-10 secretion GO:2001181 9.65 IL4 IL13
35 chemotaxis GO:0006935 9.65 RNASE2 CYSLTR1 CXCL8 CCR6 CCR3 CCL7
36 positive regulation of mast cell degranulation GO:0043306 9.64 IL4 IL13
37 negative regulation of complement-dependent cytotoxicity GO:1903660 9.62 IL4 IL13
38 immune response GO:0006955 9.44 PRG2 IL5 IL4 IL13 CXCL8 CSF2

Molecular functions related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CCR chemokine receptor binding GO:0048020 9.55 CCL7 CCL5 CCL3 CCL17 CCL11
2 lipopolysaccharide binding GO:0001530 9.54 SFTPD RNASE3 RNASE2
3 CCR5 chemokine receptor binding GO:0031730 9.43 CCL5 CCL3
4 CCR1 chemokine receptor binding GO:0031726 9.43 CCL7 CCL5 CCL3
5 chemokine activity GO:0008009 9.43 CXCL8 CCL7 CCL5 CCL3 CCL17 CCL11
6 phospholipase activator activity GO:0016004 9.4 CCL5 CCL3
7 CCR4 chemokine receptor binding GO:0031729 9.32 CCL5 CCL17
8 cytokine activity GO:0005125 9.32 IL5 IL4 IL13 CXCL8 CSF2 CCL7
Sources

Sources for Pulmonary Eosinophilia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....